Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species
Open Access
- 1 June 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (6) , 1882-1886
- https://doi.org/10.1128/aac.47.6.1882-1886.2003
Abstract
Receipt of a broad-spectrum cephalosporin is a strong risk factor for isolation of broad-spectrum cephalosporin-resistant Enterobacter species, and yet the risk from other broad-spectrum β-lactams hydrolyzed by group 1 β-lactamases has not been well characterized. We compared the risk conferred by broad-spectrum cephalosporins to that conferred by piperacillin-tazobactam, alone or in combination with an aminoglycoside or a fluoroquinolone. A retrospective cohort was monitored from treatment onset until a broad-spectrum cephalosporin-resistant Enterobacter strain was isolated or the patient was discharged. There were 447 patients in the piperacillin-tazobactam group and 2,341 patients in the broad-spectrum cephalosporin group. Groups were similar in age (mean, 62.5 years). The piperacillin-tazobactam group had a smaller percentage of men (32% versus 44%, P < 0.001) and a lower rate of intensive care unit stay (25% versus 38%, P < 0.001) but a higher rate of surgery (41% versus 26%, P < 0.001). Groups differed in the distribution of comorbidities. Resistant Enterobacter strains were isolated from 62 patients, 2% in each group (hazard ratio [RR] = 1.02 [ P = 0.95]). In multivariable analysis, risk was similar among treatment groups (RR = 0.71 [ P = 0.32]). Intensive care unit stay and surgery were associated with increased risk (RR = 4.53 [ P < 0.001] and RR = 1.97 [ P = 0.015], respectively), fluoroquinolones were protective (RR = 0.24 [ P = 0.003]), and aminoglycosides did not affect risk (RR = 0.98 [ P = 0.95]). The protective effect of fluoroquinolones against isolation of broad-spectrum cephalosporin-resistant Enterobacter spp. and the equivalence in risk associated with piperacillin-tazobactam and broad-spectrum cephalosporins may have important clinical and epidemiologic implications.Keywords
This publication has 11 references indexed in Scilit:
- Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretationClinical Microbiology & Infection, 2002
- Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter SpeciesArchives of internal medicine (1960), 2002
- Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter sppAntimicrobial Agents and Chemotherapy, 2001
- Methodological Principles of Case-Control Studies That Analyzed Risk Factors for Antibiotic Resistance: A Systematic ReviewClinical Infectious Diseases, 2001
- National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-April 2000, Issued June 2000American Journal of Infection Control, 2000
- National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, Issued June 1999American Journal of Infection Control, 1999
- Health and Economic Outcomes of Antibiotic Resistance in Pseudomonas aeruginosaArchives of internal medicine (1960), 1999
- The Relationship Between Antecedent Antibiotic Use and Resistance to Extended-Spectrum Cephalosporins in Group I -Lactamase-Producing OrganismsClinical Infectious Diseases, 1995
- Epidemiologic perspectives on Enterobacter for the infection control professionalAmerican Journal of Infection Control, 1994
- Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during TherapyAnnals of Internal Medicine, 1991